Kim Min Suk, Cho Wan Hyeong, Song Won Seok, Lee Soo-Yong, Jeon Dae-Geun
Departments of Pathology, Korea Cancer Center Hospital, Seoul, Korea.
Anticancer Res. 2007 Mar-Apr;27(2):1171-8.
Newly defined pleomorphic malignant fibrous histiocytoma represents a pleomorphic sarcoma which shows no definable line of differentiation. In this study, the survival and validity of known prognostic factors for patients with pleomorphic MFH, with the possibility of ezrin expression as a new prognostic factor were investigated.
Forty-seven patients without metastasis at presentation were analyzed. Immunohistochemical analysis with anti-ezrin antibody was performed using tissue microarray.
The overall, metastasis-free, and local recurrence-free survival rates were 59%, 57%, 52% at 5 years, respectively. Uni- and multivariate analyses revealed that truncal location and ezrin positivity had negative effects on overall and metastasis-free survival. The independent factors of local recurrence-free survival were narrow surgical margin, truncal location and female gender.
Ezrin expression was an independent predictor of distant metastasis in pleomorphic MFH. Thus, ezrin seems to provide additional prognostic information and may be a novel target for the development of new adjuvant therapies.
新定义的多形性恶性纤维组织细胞瘤是一种多形性肉瘤，无明确的分化方向。本研究调查了多形性恶性纤维组织细胞瘤患者已知预后因素的生存情况及有效性，并探讨了埃兹蛋白表达作为新的预后因素的可能性。
对47例初诊时无转移的患者进行分析。使用组织芯片进行抗埃兹蛋白抗体的免疫组化分析。
5年时的总生存率、无转移生存率和无局部复发生存率分别为59%、57%、52%。单因素和多因素分析显示，躯干部位和埃兹蛋白阳性对总生存和无转移生存有负面影响。无局部复发生存的独立因素为手术切缘窄、躯干部位和女性性别。
埃兹蛋白表达是多形性恶性纤维组织细胞瘤远处转移的独立预测因素。因此，埃兹蛋白似乎能提供额外的预后信息，可能是开发新辅助治疗的新靶点。
Zotero 插件